3 Reasons to Buy Bristol-Myers Squibb
Shares of Bristol-Myers Squibb , one of the largest pharmaceutical companies in the world, have been on a steady climb since the start of 2013. While Bristol is still facing headwinds from the patent expiration of its blockbuster drug, Plavix, recent clinical trial data have reignited investor enthusiasm for Bristol's long-term prospects. In the following segment from The Motley Fool's health care show, analysts David Williamson and Max Macaluso discuss three reasons investors might consider buying this pharma stock.
One of the best parts of owning big pharma stocks like Bristol-Myers Squibb is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article 3 Reasons to Buy Bristol-Myers Squibb originally appeared on Fool.com.
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
